December 2021 - Page 4 of 4 - BioMedWire (BMW)

MondayDec 06, 2021 9:30 am

Missed Eating Disorder Diagnoses in Men Are on the Rise

Eating disorders are severe mental and physical illnesses that encompass damaging relationships with body image, exercise, eating and food. Research has found that behaviors that are linked to eating disorders, such as fasting for weight loss, purging and binge eating, are almost as common in men as they are in women. Figures from the National Eating Disorders Association also show that every one in three individuals suffering from an eating disorder is male. A study that was recently published in the “American Journal of Men’s Health” has found that eating disorder prevalence in men has been increasing, with data showing…

FridayDec 03, 2021 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Research and Technology Progress, Offers Corporate Update

Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platform MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide In July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good Laboratory Practice (“GLP”) ibogaine, which will lead to the production of Good Manufacturing Practice (“GMP”) ibogaine to scale and manufacture a global supply of its synthetic ibogaine In addition to this pre-clinical trial,…

FridayDec 03, 2021 9:30 am

Baby Teeth Could Help Reveal Mental Illness Risk in Children

A new study has found that the growth lines in baby teeth may be used to identify children who are at risk for mental health conditions such as depression later in life. The study, which was conducted by researchers at the Massachusetts General Hospital, published its findings in JAMA Network Open. Researchers believe that their discovery could assist in the development of a tool that can identify children who have been exposed to adversity early in their lives. Early-life adversity is a risk factor for psychological issues. Erin C. Dunn, a social and psychiatric epidemiologist who studies the impact of…

ThursdayDec 02, 2021 9:30 am

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

NMRD releases fiscal Q2-2021 results, provides business update Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286). Financial highlights from the announcement included $26.8M cash on hand, and receipt of…

ThursdayDec 02, 2021 9:30 am

Study Finds That Holiday Season May Worsen Mental Health

A recent study conducted by the National Alliance of Mental Illness has found that symptoms of mental illness may worsen during the holiday season. Participants who were part of the study who suffered from various mental health conditions admitted that their conditions worsened during the holiday season. Pamela Mairs, a licensed psychologist who was part of the study, stated that the coronavirus pandemic had on its own triggered increased mental health conditions in adults. She explained that hopelessness, fear about the future, anxiety, withdrawal and depression had been observed in adults. The CDC recently released a guide for the holiday…

ThursdayDec 02, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

Report notes significant and swift advancements in company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period…

WednesdayDec 01, 2021 9:30 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Releases Q3 Update, Details JHU Five-Year Research Agreement

Mydecine’s recent Q3 update includes the company’s five-year research agreement with Johns Hopkins University School of Medicine, which will cover clinical research related to the therapeutic use of psychedelics Mydecine has also filed for various patents on proprietary compounds within the company’s IP portfolio In addition, an updated version of the company’s virtual health platform, Mindleap 2.0, was released in Q3, enhancing user experience, infrastructure improvement, and expansion of overall content Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), a company that focuses on bio- and digital technology that aims to transform the treatment of mental health and addiction…